PEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: A tissue-microarray study with clinic-pathological correlations

Cancer Biology and Therapy

Volumn 13, Issue 11, 2012, Pages 967-977

  Aquino, Gabriella ^a   Pannone, Giuseppe ^b   Santoro, Angela ^c   Liguori, Giuseppina ^a   Franco, Renato ^a   Serpico, Rosario ^d   Florio, Gianluca ^d   De Rosa, Alfredo ^d   Mattoni, Marilena ^b   Cozza, Valentina ^e   Botti, Gerardo ^a   Losito, Simona ^a   Longo, Francesco ^a   Staibano, Stefania ^f   Cuda, Giovanni ^g   Muzio, Lorenzo Lo ^b   Sbordone, Carolina ^f   Bufo, Pantaleo ^b   Grimaldi, Anna ^d   Caraglia, Michele ^d   Di Domenico, Marina ^d,h   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^h TEMPLE UNIVERSITY   (United States)

Author keywords

EGFR; OSCC; Phosphorylated EGFR; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER; TYROSINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MOUTH MUCOSA; MOUTH SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SRC HOMOLOGY DOMAIN; TISSUE MICROARRAY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PARAFFIN EMBEDDING; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TYROSINE;

EID: 84865852812     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20991     Document Type: Article

References (61)

1. Son YH, Kapp DS. Oral cavity and oropharyngeal cancer in a younger population. Review of literature and experience at Yale. Cancer 1985; 55:441-4; PMID:3965099; http://dx.doi.org/10.1002/1097-0142(19850115)55:2〈441:: AIDCNCR2820550225〉3.0.CO;2-5.
2. Chen YJ, Lin SC, Kao T, Chang CS, Hong PS, Shieh TM, et al. Genome-wide profiling of oral squamous cell carcinoma. J Pathol 2004; 204:326-32; PMID:15372456; http://dx.doi.org/10.1002/path.1640.
3. Magrath I, Litvak J. Cancer in developing countries: opportunity and challenge. J Natl Cancer Inst 1993; 85:862-74; PMID:8492315; http://dx.doi.org/10.1093/jnci/85.11.862.
4. Sciubba JJ. Oral cancer. The importance of early diagnosis and treatment. Am J Clin Dermatol 2001; 2:239-51; PMID:11705251; http://dx.doi.org/10.2165/ 00128071-200102040-00005.
5. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37:3-8; PMID:11597398; http://dx.doi.org/10.1016/S0959-8049(01)00230-1.
6. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002; 24:165-80; PMID:11891947; http://dx.doi.org/ 10.1002/hed.10004.
7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007; 57:43-66; PMID:17237035; http://dx.doi.org/10.3322/ canjclin.57.1.43.
8. Eley GD, Reiter JL, Pandita A, Park S, Jenkins RB, Maihle NJ, et al. A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma. Neurooncol 2002; 4:86-94; PMID:11916499.
9. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, et al. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage and favorable outcome in 717 colorectal cancers. Cancer 2011; 117:1399-408; PMID:21425139; http://dx.doi.org/10.1002/cncr.25630.
10. Poppleton HM, Wiepz GJ, Bertics PJ, Patel TB. Modulation of the protein tyrosine kinase activity and autophosphorylation of the epidermal growth factor receptor by its juxtamembrane region. Arch Biochem Biophys 1999; 363:227-36; PMID:10068444; http://dx.doi.org/10.1006/abbi.1998.1095.
11. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use and tobacco control. J Natl Cancer Inst 2008; 100:1672-94; PMID:19033571; http://dx.doi.org/10.1093/jnci/djn389.
12. Tateda M, Shiga K, Yoshida H, Saijo S, Yokoyama J, Nishikawa H, et al. Management of the patients with hypopharyngeal cancer: eight-year experience of Miyagi Cancer Center in Japan. Tohoku J Exp Med 2005; 205:65-77; PMID:15635275; http://dx.doi.org/10.1620/tjem.205.65.
13. Shiga K, Tateda M, Saijo S, Hori T, Sato I, Tateno H, et al. Presence of Streptococcus infection in extraoropharyngeal head and neck squamous cell carcinoma and its implication in carcinogenesis. Oncol Rep 2001; 8:245-8; PMID:11182034.
14. Hooper SJ, Crean SJ, Lewis MA, Spratt DA, Wade WG, Wilson MJ. Viable bacteria present within oral squamous cell carcinoma tissue. J Clin Microbiol 2006; 44:1719-25; PMID:16672398; http://dx.doi.org/10.1128/JCM.44.5.1719-25. 2006.
15. Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006; 94:184-8; PMID:16434982; http://dx.doi.org/10.1038/sj.bjc. 6602941.
16. Hiraishi Y, Wada T, Nakatani K, Tojyo I, Matsumoto T, Kiga N, et al. EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines. Pathol Oncol Res 2008; 14:39-43; PMID:18347929; http://dx.doi.org/10. 1007/s12253-008-9020-5.
17. Park SJ, Kim MJ, Kim YK, Kim SM, Park JY, Myoung H. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma. Cancer Lett 2010; 292:54-63; http://dx.doi.org/10.1016/j.canlet.2009. 11.004; PMID:19959278.
18. Li T, Ling YH, Perez-Soler R. Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene. J Thorac Oncol 2008; 3:643-7; PMID:18520805; http://dx.doi.org/10.1097/JTO. 0b013e3181753b24.
19. Kalish LH, Kwong RA, Cole IE, Gallagher RM, Sutherland RL, Musgrove EA. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004; 10:7764-74; PMID:15570011; http://dx.doi.org/10.1158/1078-0432.CCR-04-0012.
20. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19:3234-43; PMID:11432891.
21. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-8; http://dx.doi.org/10.1016/S1470-2045(09)70311-0.
22. Caudell JJ, Sawrie SM, Spencer SA, Desmond RA, Carroll WR, Peters GE, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 2008; 71:676-81; PMID: 18355979.
23. Lord HK, Junor E, Ironside J. Cetuximab is effective, but more toxic than reported in the Bonner trial. Clin Oncol (R Coll Radiol) 2008; 20:96; PMID:17928207; http://dx.doi.org/10.1016/j.clon.2007.09.003.
24. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature 1984; 311:483-5; PMID:6090945; http://dx.doi.org/10.1038/311483a0.
25. Yip WK, Leong VC, Abdullah MA, Yusoff S, Seow HF. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep 2008; 19:319-28; PMID:18202777.
26. Wallerand H, Cai Y, Wainberg ZA, Garraway I, Lascombe I, Nicolle G, et al. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Urol Oncol 2010; 28:180-8; PMID:19070520; http://dx.doi.org/10.1016/j.urolonc.2008.09.041.
27. Kannangai R, Sahin F, Torbenson MS. EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol 2006; 19:1456-61; PMID:16936701; http://dx.doi.org/10.1038/modpathol.3800665.
28. Tsakiridis T, Cutz JC, Singh G, Hirte H, Okawara G, Corbett T, et al. Association of phosphorylated epidermal growth factor receptor with survival in patients with locally advanced non-small cell lung cancer treated with radiotherapy. J Thorac Oncol 2008; 3:716-22; PMID:18594316; http://dx.doi.org/ 10.1097/JTO.0b013e31817c6094.
29. McMillen E, Ye F, Li G, Wu Y, Yin G, Liu W. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Exp Lung Res 2010; 36:531-7; PMID:20939760; http://dx.doi.org/10.3109/ 01902148.2010.482176.
30. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001; 61:7196-203; PMID:11585755.
31. Kazkayasi M, Hücümeno lu S, Siriner GI, Hücümeno lu M. Overexpression of p53 and c-erbB-2 oncoproteins in laryngeal carcinoma. Eur Arch Otorhinolaryngol 2001; 258:329-35; PMID:11699821; http://dx.doi.org/10. 1007/s004050100346.
32. Franchi A, Fondi C, Paglierani M, Pepi M, Gallo O, Santucci M. Epidermal growth factor receptor expression and gene copy number in sinonasal intestinal type adenocarcinoma. Oral Oncol 2009; 45:835-8; PMID:19213595; http://dx.doi.org/10.1016/j.oraloncology.2008.12.005.
33. Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, et al. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic and mutational analysis study. Mod Pathol 2008; 21:1168-75; PMID:18587327; http://dx.doi.org/10.1038/modpathol.2008.113.
34. Di Domenico M, Castoria G, Bilancio A, Migliaccio A, Auricchio F. Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res 1996; 56:4516-21; PMID:8813150.
35. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24:2666-72; PMID:16763281; http://dx.doi.org/10.1200/JCO.2005.04.8306.
36. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24:4170-6; PMID:16943533; http://dx.doi.org/10.1200/JCO.2006.07.2587.
37. Lin SC, Liu CJ, Ko SY, Chang HC, Liu TY, Chang KW. Copy number amplification of 3q26-27 oncogenes in microdissected oral squamous cell carcinoma and oral brushed samples from areca chewers. J Pathol 2005; 206:417-22; PMID:15906274; http://dx.doi.org/10.1002/path.1790.
38. Hiraishi Y, Wada T, Nakatani K, Negoro K, Fujita S. Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas. Pathol Oncol Res 2006; 12:87-91; PMID:16799709; http://dx.doi.org/10.1007/BF02893450.
39. Schwartz JL, Muscat JE, Baker V, Larios E, Stephenson GD, Guo W, et al. Oral cytology assessment by flow cytometry of DNA adducts, aneuploidy, proliferation and apoptosis shows differences between smokers and non-smokers. Oral Oncol 2003; 39:842-54; PMID:13679208; http://dx.doi.org/10.1016/S1368- 8375(03)00107-6.
40. Franco R, Caraglia M, Facchini G, Abbruzzese A, Botti G. The role of tissue microarray in the era of target-based agents. Expert Rev Anticancer Ther 2011; 11:859-69; PMID:21707283; http://dx.doi.org/10.1586/era.11.65.
41. Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11:5856-62; PMID:16115926; http://dx.doi.org/10.1158/1078-0432.CCR-05-0420.
42. Bei R, Pompa G, Vitolo D, Moriconi E, Ciocci L, Quaranta M, et al. Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol 2001; 195:343-8; PMID:11673832; http://dx.doi.org/10.1002/path.965.
43. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factoralpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78:1284-92; PMID:8826952; http://dx.doi.org/10.1002/(SICI) 1097-0142(19960915)78:6〈1284::AIDCNCR17〉3.0.CO;2-X.
44. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328:184-94; PMID:8417385; http://dx.doi.org/10.1056/ NEJM199301213280306.
45. Boerner JL, Biscardi JS, Silva CM, Parsons SJ. Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis. Mol Carcinog 2005; 44:262-73; PMID:16167350; http://dx.doi.org/10. 1002/mc.20138.
46. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999; 274:8335-43; PMID:10075741; http://dx.doi.org/10.1074/jbc.274.12.8335.
47. Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, et al. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS ONE 2011; 6:28053; PMID:22140506; http://dx.doi.org/10.1371/journal.pone.0028053.
48. Cheng SJ, Kok SH, Lee JJ, Yen-Ping Kuo M, Cheng SL, Huang YL, et al. Significant association of SRC protein expression with the progression, recurrence and prognosis of oral squamous cell carcinoma in Taiwan. Head Neck 2011; PMID:22052839; http://dx.doi.org/10.1002/hed.21923.
49. Sen B, Peng S, Saigal B, Williams MD, Johnson FM. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res 2011; 17:514-24; PMID:21106725; http://dx.doi.org/10.1158/1078-0432.CCR-10-1617.
50. Pannone G, Santoro A, Papagerakis S, Lo Muzio L, De Rosa G, Bufo P. The role of human papillomavirus in the pathogenesis of head & neck squamous cell carcinoma: an overview. Infect Agent Cancer 2011; 6:4; PMID:21447181; http://dx.doi.org/10.1186/1750-9378-6-4.
51. Pannone G, Rodolico V, Santoro A, Lo Muzio L, Franco R, Botti G, et al. Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer 2012; 7:4; PMID:22376902; http://dx.doi.org/10.1186/1750-9378-7-4.
52. Scapoli L, Palmieri A, Rubini C, Martinelli M, Spinelli G, Ionna F, et al. Low prevalence of human papillomavirus in squamous-cell carcinoma limited to oral cavity proper. Mod Pathol 2009; 22:366-72; PMID:18978731; http://dx.doi.org/10.1038/modpathol.2008.180.
53. Delhanty PJ, van Koetsveld PM, Gauna C, van de Zande B, Vitale G, Hofland LJ, et al. Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway. Am J Physiol Endocrinol Metab 2007; 293:302-9; PMID:17405826; http://dx.doi.org/10.1152/ ajpendo.00377.2006.
54. Vitale G, van Eijck CH, van Koetsveld Ing PM, Erdmann JI, Speel EJ, van der Wansem Ing K, et al. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg 2007; 246:259-68; PMID:17667505; http://dx.doi.org/10.1097/01.sla.0000261460.07110.f2.
55. Vitale G, van Koetsveld PM, de Herder WW, van der Wansem K, Janssen JA, Colao A, et al. Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. Am J Physiol Endocrinol Metab 2009; 296:559-66; PMID:19141687; http://dx.doi.org/10.1152/ ajpendo.90770.2008.
56. Caraglia M, Marra M, Tagliaferri P, Lamberts SW, Zappavigna S, Misso G, et al. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets 2009; 9:690-704; PMID:19508175; http://dx.doi.org/10.2174/156800909789056980.
57. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993; 85:95-111; PMID:8418313; http://dx.doi.org/10.1093/jnci/85.2.95.
58. Green MR. Targeting targeted therapy. N Engl J Med 2004; 350:2191-3; PMID:15118072; http://dx.doi.org/10.1056/NEJMe048101.
59. Gamel JW, Jones AS. Squamous carcinoma of the head and neck: cured fraction and median survival time as functions of age, sex, histologic type and node status. Br J Cancer 1993; 67:1071-5; PMID:8494700; http://dx.doi.org/10. 1038/bjc.1993.196.
60. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85; PMID:14701768; http://dx.doi.org/10.1200/JCO.2004.06.075.
61. Magné N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 2002; 86:1518-23; PMID:11986789; http://dx.doi.org/10.1038/sj.bjc.6600299.